AlphaQuest LLC Has $34,000 Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

AlphaQuest LLC lifted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 138.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 931 shares of the medical device company’s stock after purchasing an additional 541 shares during the quarter. AlphaQuest LLC’s holdings in Tandem Diabetes Care were worth $34,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TNDM. Natixis Advisors LLC boosted its position in shares of Tandem Diabetes Care by 19.6% in the 3rd quarter. Natixis Advisors LLC now owns 63,706 shares of the medical device company’s stock valued at $2,702,000 after purchasing an additional 10,462 shares during the period. Commerce Bank lifted its stake in Tandem Diabetes Care by 40.9% in the 3rd quarter. Commerce Bank now owns 22,164 shares of the medical device company’s stock worth $940,000 after acquiring an additional 6,437 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Tandem Diabetes Care by 32.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 272,097 shares of the medical device company’s stock worth $11,540,000 after acquiring an additional 66,687 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Tandem Diabetes Care by 17.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 10,200 shares of the medical device company’s stock worth $433,000 after acquiring an additional 1,525 shares in the last quarter. Finally, Intech Investment Management LLC lifted its stake in Tandem Diabetes Care by 156.0% in the 3rd quarter. Intech Investment Management LLC now owns 18,336 shares of the medical device company’s stock worth $778,000 after acquiring an additional 11,173 shares in the last quarter.

Tandem Diabetes Care Stock Down 1.7 %

Shares of TNDM stock opened at $20.29 on Friday. The stock’s 50 day simple moving average is $29.70 and its 200 day simple moving average is $33.86. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a twelve month low of $17.64 and a twelve month high of $53.69. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -10.51 and a beta of 1.45.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on TNDM. Morgan Stanley downgraded Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. Sanford C. Bernstein downgraded Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Citigroup downgraded Tandem Diabetes Care from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group reduced their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.38.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.